» Articles » PMID: 9635923

Antiproliferative Effects of Recombinant Human Bone Morphogenetic Protein-2 on Human Tumor Colony-forming Units

Overview
Specialty Oncology
Date 1998 Jun 23
PMID 9635923
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Bone morphogenetic protein-2 (BMP-2) is a differentiation factor for normal osteoblasts. BMP-2 is structurally related to transforming growth factor-beta which inhibits cell proliferation and enhances apoptosis. A recent study has shown the presence of BMP-2 receptors on several cancer cell lines. In this study, we attempted to determine if recombinant human BMP-2 (rhBMP-2) can modulate the proliferation of human tumor colony-forming units taken from 113 patients. Tumor cells were cultured in soft agar and continuously exposed to three concentrations of rhBMP-2 (10, 100 and 1000 ng/ml) for 14 days in the capillary cloning system. There were 65 evaluable specimens, including 17 breast cancers, 15 ovarian cancers, 14 non-small cell lung cancers and five prostate cancers. Importantly, rhBMP-2 did not stimulate the tumor cell proliferation. A significant inhibition (50% or less survival of tumor colony-forming units) was seen in 16 of 65 specimens (24.6%) at 1000 ng/ml, including five of 14 non-small cell lung cancers, five of 17 breast tumors and two of 15 ovarian tumors. A concentration-response relationship was observed (p<0.001 by Mantel-extension test). The results of this study encourage further evaluation of the antiproliferative effects of rhBMP-2 against human cancers.

Citing Articles

Bone morphogenetic protein signaling is a possible therapeutic target in gynecologic cancer.

Fukuda T, Suzuki E, Fukuda R Cancer Sci. 2022; 114(3):722-729.

PMID: 36468782 PMC: 9986083. DOI: 10.1111/cas.15682.


Risk of Cancer Following Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rhBMP-2): An Analysis Using a Commercially Insured Patient Population.

Cooper G, Kou T Int J Spine Surg. 2018; 12(2):260-268.

PMID: 30276083 PMC: 6159730. DOI: 10.14444/50323.


Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance.

Zabkiewicz C, Resaul J, Hargest R, Jiang W, Ye L Endocr Relat Cancer. 2017; 24(10):R349-R366.

PMID: 28733469 PMC: 5574206. DOI: 10.1530/ERC-17-0139.


Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition.

Jiramongkolchai P, Owens P, Hong C Biochem Soc Trans. 2016; 44(4):1117-34.

PMID: 27528760 PMC: 5483997. DOI: 10.1042/BST20160069.


Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis.

Pickup M, Hover L, Guo Y, Gorska A, Chytil A, Novitskiy S Oncotarget. 2015; 6(26):22890-904.

PMID: 26274893 PMC: 4673207. DOI: 10.18632/oncotarget.4413.